Delpharm and the Famar Group announce the acquisition by Delpharm of 5 manufacturing sites in France, Canada and the Netherlands.
Delpharm and the Famar Group are pleased to announce the acquisition by Delpharm of 5 manufacturing sites belonging to Famar, in France, Canada and the Netherlands. The transaction signed today covers the French sites located in Orléans (Loiret), L’Aigle (Orne) and Saint-Rémy-sur-Avre (Eure-et-Loire), as well as the Montreal site in Canada and that of Bladel in the Netherlands.
The transaction signed today covers the French sites located in Orléans (Loiret), L’Aigle (Orne) and Saint-Rémy-sur-Avre (Eure-et-Loire), as well as the Montreal site in Canada and that of Bladel in the Netherlands. The group of 5 sites represents a turnover of 250M€ and 1,300 employees.
Patrick Puy, President of Famar: « This acquisition by Delpharm, a reputable CDMO, represents a great opportunity for the 1300 Famar colleagues and will allow the sites to foresee a fruitful and sustainable future. »
Sébastien Aguettant, President of Delpharm: « With an headcount of 4700 people working on 17 manufacturing sites, Delpharm is reaching a new level and is now part of the top 5 CDMOs worldwide. »
Delpharm and the Famar Group wish to thank all the stakeholders who worked hard to make this deal happen, especially the French authorities, for their positive involvement.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance